Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy
•Dose-escalated IG-IMRT results in good LC & CSS in OGS, CS and CH of H&N and pelvis.•No significant difference in outcomes for definitive versus post-operative RT.•Significant and sustained benefit in functional outcomes after RT.•Acute & late toxicities were minimal despite escalated d...
Gespeichert in:
| Veröffentlicht in: | Radiotherapy and oncology 2021-11, Vol.164, p.216-222 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 222 |
|---|---|
| container_issue | |
| container_start_page | 216 |
| container_title | Radiotherapy and oncology |
| container_volume | 164 |
| creator | Laskar, Siddhartha Kakoti, Sangeeta Khanna, Nehal Manjali, Jifmi Jose Mangaj, Akshay Puri, Ajay Gulia, Ashish Nayak, Prakash Pai, Prathamesh Nair, Deepa Qureshi, Sajid Chinnaswamy, Girish Bajpai, Jyoti Prabhash, Kumar Rekhi, Bharat Ramadwar, Mukta Jambhekar, Nirmala Janu, Amit Juvekar, Sashikant Purandare, Nilendu Rangarajan, Venkatesh |
| description | •Dose-escalated IG-IMRT results in good LC & CSS in OGS, CS and CH of H&N and pelvis.•No significant difference in outcomes for definitive versus post-operative RT.•Significant and sustained benefit in functional outcomes after RT.•Acute & late toxicities were minimal despite escalated doses.•Salvage re-RT is feasible and efficacious in recurrence after dose-escalated IG-IMRT.
To evaluate the efficacy and toxicity of dose-escalated image guided-intensity modulated radiation therapy (IG-IMRT) in osteosarcoma (OGS), chondrosarcoma (CS) and chordoma (CH) of head and neck (H&N) and pelvis.
In this prospective non-randomized study, 65 patients of H&N or pelvic OGS (24), CS (7) and CH (34) mandating definitive or post-operative radiotherapy from May 2013 to December 2018 were included. Radiotherapy doses in definitive setting were 72.0 Gy for CH and 70.2 Gy for OGS and CS; while in post-operative setting it was 66.6 Gy and 64.8 Gy respectively (at 1.8 Gy per fraction).
Planned doses of radiotherapy could be completed in 61 (93.8%) patients; with grade III or higher acute and late toxicities of 3% and 0% respectively. With a median follow-up of 52 (range 6–92) months, the five-year actuarial local control (LC) rates were 66% in OGS, 38.1% in CS and 75.9% in CH; while cause-specific survival (CSS) rates were 54.7%, 64.3% and 92.2% respectively. There was no statistically significant difference in outcomes for patients receiving definitive and post-operative radiotherapy. Locally controlled disease at first follow-up after radiotherapy was associated with improved CSS and OS in CS (p = 0.014) and CH (p |
| doi_str_mv | 10.1016/j.radonc.2021.09.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_miscellaneous_2578772534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167814021067414</els_id><sourcerecordid>2578772534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-a49a0b766cd6dc32536ef3d7e85524e9400f283f128cd5fcdf795d8a36d0fc3f3</originalsourceid><addsrcrecordid>eNqNkU1r3DAQhkVpabZp_0EpPhYaO_qyJV8KZWnaQCCX5iy00iirZW1tJTlh_33leJNjyUmMeN6R5hmEPhPcEEy6y10TtQ2jaSimpMF9g4l8g1ZEir7GUoq3aFUwUUvC8Rn6kNIOY0wxE-_RGeNtLwQTKzTdTtmEAVIVXBVShpB0LBf6ojLbMNr4XFd6tPNVtHORI-gMtnr0eVv5Qd9DdT95C7b2Y4Yx-XyshmCn_RNVPup19mGs8haiPhw_ondO7xN8Op3n6O7q55_17_rm9tf1-sdNbVhHc615r_FGdJ2xnTWMtqwDx6wA2baUQ88xdlQyR6g0tnXGOtG3VmrWWewMc-wcfV36HmL4O0HKavDJwH6vRwhTUrQVUojSlxeUL6gpI6cITh1iGSweFcFqFq52ahGuZuEK96oIL7EvpxemzQD2JfRsuAByAR5hE1wyHkYDL1hZicCSc0Lm5fC1z0-e1mEac4l-e3200N8XGorQBw9RnRLWRzBZ2eD_P8o_bSy3SQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2578772534</pqid></control><display><type>article</type><title>Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy</title><source>MEDLINE</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Access via ScienceDirect (Elsevier)</source><creator>Laskar, Siddhartha ; Kakoti, Sangeeta ; Khanna, Nehal ; Manjali, Jifmi Jose ; Mangaj, Akshay ; Puri, Ajay ; Gulia, Ashish ; Nayak, Prakash ; Pai, Prathamesh ; Nair, Deepa ; Qureshi, Sajid ; Chinnaswamy, Girish ; Bajpai, Jyoti ; Prabhash, Kumar ; Rekhi, Bharat ; Ramadwar, Mukta ; Jambhekar, Nirmala ; Janu, Amit ; Juvekar, Sashikant ; Purandare, Nilendu ; Rangarajan, Venkatesh</creator><creatorcontrib>Laskar, Siddhartha ; Kakoti, Sangeeta ; Khanna, Nehal ; Manjali, Jifmi Jose ; Mangaj, Akshay ; Puri, Ajay ; Gulia, Ashish ; Nayak, Prakash ; Pai, Prathamesh ; Nair, Deepa ; Qureshi, Sajid ; Chinnaswamy, Girish ; Bajpai, Jyoti ; Prabhash, Kumar ; Rekhi, Bharat ; Ramadwar, Mukta ; Jambhekar, Nirmala ; Janu, Amit ; Juvekar, Sashikant ; Purandare, Nilendu ; Rangarajan, Venkatesh</creatorcontrib><description><![CDATA[•Dose-escalated IG-IMRT results in good LC & CSS in OGS, CS and CH of H&N and pelvis.•No significant difference in outcomes for definitive versus post-operative RT.•Significant and sustained benefit in functional outcomes after RT.•Acute & late toxicities were minimal despite escalated doses.•Salvage re-RT is feasible and efficacious in recurrence after dose-escalated IG-IMRT.
To evaluate the efficacy and toxicity of dose-escalated image guided-intensity modulated radiation therapy (IG-IMRT) in osteosarcoma (OGS), chondrosarcoma (CS) and chordoma (CH) of head and neck (H&N) and pelvis.
In this prospective non-randomized study, 65 patients of H&N or pelvic OGS (24), CS (7) and CH (34) mandating definitive or post-operative radiotherapy from May 2013 to December 2018 were included. Radiotherapy doses in definitive setting were 72.0 Gy for CH and 70.2 Gy for OGS and CS; while in post-operative setting it was 66.6 Gy and 64.8 Gy respectively (at 1.8 Gy per fraction).
Planned doses of radiotherapy could be completed in 61 (93.8%) patients; with grade III or higher acute and late toxicities of 3% and 0% respectively. With a median follow-up of 52 (range 6–92) months, the five-year actuarial local control (LC) rates were 66% in OGS, 38.1% in CS and 75.9% in CH; while cause-specific survival (CSS) rates were 54.7%, 64.3% and 92.2% respectively. There was no statistically significant difference in outcomes for patients receiving definitive and post-operative radiotherapy. Locally controlled disease at first follow-up after radiotherapy was associated with improved CSS and OS in CS (p = 0.014) and CH (p < 0.001). Radiotherapy resulted in significant and sustained improvement in Musculoskeletal tumour society (MSTS) score and reduction in pain score. Salvage re-irradiation was feasible in local progression after radiotherapy, with good outcomes and tolerability.
Dose-escalated IG-IMRT results in good LC & functional improvement with minimal toxicity in OGS, CS and CH.]]></description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/j.radonc.2021.09.018</identifier><identifier>PMID: 34597737</identifier><language>eng</language><publisher>CLARE: Elsevier B.V</publisher><subject>Bone Neoplasms ; Chondrosarcoma - radiotherapy ; Chordoma - radiotherapy ; Dose escalation ; Humans ; Intensity modulated radiotherapy ; Life Sciences & Biomedicine ; Oncology ; Osteosarcoma - radiotherapy ; Prospective Studies ; Radiology, Nuclear Medicine & Medical Imaging ; Radiotherapy Dosage ; Radiotherapy, Intensity-Modulated - adverse effects ; Sarcoma ; Science & Technology</subject><ispartof>Radiotherapy and oncology, 2021-11, Vol.164, p.216-222</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000708441100024</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c362t-a49a0b766cd6dc32536ef3d7e85524e9400f283f128cd5fcdf795d8a36d0fc3f3</citedby><cites>FETCH-LOGICAL-c362t-a49a0b766cd6dc32536ef3d7e85524e9400f283f128cd5fcdf795d8a36d0fc3f3</cites><orcidid>0000-0003-2581-3086 ; 0000-0002-5133-7442 ; 0000-0002-3509-4794 ; 0000-0002-3560-9655 ; 0000-0002-8385-2836 ; 0000-0001-9989-5534 ; 0000-0002-4323-753X ; 0000-0001-7657-3460</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.radonc.2021.09.018$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,39263,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34597737$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laskar, Siddhartha</creatorcontrib><creatorcontrib>Kakoti, Sangeeta</creatorcontrib><creatorcontrib>Khanna, Nehal</creatorcontrib><creatorcontrib>Manjali, Jifmi Jose</creatorcontrib><creatorcontrib>Mangaj, Akshay</creatorcontrib><creatorcontrib>Puri, Ajay</creatorcontrib><creatorcontrib>Gulia, Ashish</creatorcontrib><creatorcontrib>Nayak, Prakash</creatorcontrib><creatorcontrib>Pai, Prathamesh</creatorcontrib><creatorcontrib>Nair, Deepa</creatorcontrib><creatorcontrib>Qureshi, Sajid</creatorcontrib><creatorcontrib>Chinnaswamy, Girish</creatorcontrib><creatorcontrib>Bajpai, Jyoti</creatorcontrib><creatorcontrib>Prabhash, Kumar</creatorcontrib><creatorcontrib>Rekhi, Bharat</creatorcontrib><creatorcontrib>Ramadwar, Mukta</creatorcontrib><creatorcontrib>Jambhekar, Nirmala</creatorcontrib><creatorcontrib>Janu, Amit</creatorcontrib><creatorcontrib>Juvekar, Sashikant</creatorcontrib><creatorcontrib>Purandare, Nilendu</creatorcontrib><creatorcontrib>Rangarajan, Venkatesh</creatorcontrib><title>Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy</title><title>Radiotherapy and oncology</title><addtitle>RADIOTHER ONCOL</addtitle><addtitle>Radiother Oncol</addtitle><description><![CDATA[•Dose-escalated IG-IMRT results in good LC & CSS in OGS, CS and CH of H&N and pelvis.•No significant difference in outcomes for definitive versus post-operative RT.•Significant and sustained benefit in functional outcomes after RT.•Acute & late toxicities were minimal despite escalated doses.•Salvage re-RT is feasible and efficacious in recurrence after dose-escalated IG-IMRT.
To evaluate the efficacy and toxicity of dose-escalated image guided-intensity modulated radiation therapy (IG-IMRT) in osteosarcoma (OGS), chondrosarcoma (CS) and chordoma (CH) of head and neck (H&N) and pelvis.
In this prospective non-randomized study, 65 patients of H&N or pelvic OGS (24), CS (7) and CH (34) mandating definitive or post-operative radiotherapy from May 2013 to December 2018 were included. Radiotherapy doses in definitive setting were 72.0 Gy for CH and 70.2 Gy for OGS and CS; while in post-operative setting it was 66.6 Gy and 64.8 Gy respectively (at 1.8 Gy per fraction).
Planned doses of radiotherapy could be completed in 61 (93.8%) patients; with grade III or higher acute and late toxicities of 3% and 0% respectively. With a median follow-up of 52 (range 6–92) months, the five-year actuarial local control (LC) rates were 66% in OGS, 38.1% in CS and 75.9% in CH; while cause-specific survival (CSS) rates were 54.7%, 64.3% and 92.2% respectively. There was no statistically significant difference in outcomes for patients receiving definitive and post-operative radiotherapy. Locally controlled disease at first follow-up after radiotherapy was associated with improved CSS and OS in CS (p = 0.014) and CH (p < 0.001). Radiotherapy resulted in significant and sustained improvement in Musculoskeletal tumour society (MSTS) score and reduction in pain score. Salvage re-irradiation was feasible in local progression after radiotherapy, with good outcomes and tolerability.
Dose-escalated IG-IMRT results in good LC & functional improvement with minimal toxicity in OGS, CS and CH.]]></description><subject>Bone Neoplasms</subject><subject>Chondrosarcoma - radiotherapy</subject><subject>Chordoma - radiotherapy</subject><subject>Dose escalation</subject><subject>Humans</subject><subject>Intensity modulated radiotherapy</subject><subject>Life Sciences & Biomedicine</subject><subject>Oncology</subject><subject>Osteosarcoma - radiotherapy</subject><subject>Prospective Studies</subject><subject>Radiology, Nuclear Medicine & Medical Imaging</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, Intensity-Modulated - adverse effects</subject><subject>Sarcoma</subject><subject>Science & Technology</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><recordid>eNqNkU1r3DAQhkVpabZp_0EpPhYaO_qyJV8KZWnaQCCX5iy00iirZW1tJTlh_33leJNjyUmMeN6R5hmEPhPcEEy6y10TtQ2jaSimpMF9g4l8g1ZEir7GUoq3aFUwUUvC8Rn6kNIOY0wxE-_RGeNtLwQTKzTdTtmEAVIVXBVShpB0LBf6ojLbMNr4XFd6tPNVtHORI-gMtnr0eVv5Qd9DdT95C7b2Y4Yx-XyshmCn_RNVPup19mGs8haiPhw_ondO7xN8Op3n6O7q55_17_rm9tf1-sdNbVhHc615r_FGdJ2xnTWMtqwDx6wA2baUQ88xdlQyR6g0tnXGOtG3VmrWWewMc-wcfV36HmL4O0HKavDJwH6vRwhTUrQVUojSlxeUL6gpI6cITh1iGSweFcFqFq52ahGuZuEK96oIL7EvpxemzQD2JfRsuAByAR5hE1wyHkYDL1hZicCSc0Lm5fC1z0-e1mEac4l-e3200N8XGorQBw9RnRLWRzBZ2eD_P8o_bSy3SQ</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Laskar, Siddhartha</creator><creator>Kakoti, Sangeeta</creator><creator>Khanna, Nehal</creator><creator>Manjali, Jifmi Jose</creator><creator>Mangaj, Akshay</creator><creator>Puri, Ajay</creator><creator>Gulia, Ashish</creator><creator>Nayak, Prakash</creator><creator>Pai, Prathamesh</creator><creator>Nair, Deepa</creator><creator>Qureshi, Sajid</creator><creator>Chinnaswamy, Girish</creator><creator>Bajpai, Jyoti</creator><creator>Prabhash, Kumar</creator><creator>Rekhi, Bharat</creator><creator>Ramadwar, Mukta</creator><creator>Jambhekar, Nirmala</creator><creator>Janu, Amit</creator><creator>Juvekar, Sashikant</creator><creator>Purandare, Nilendu</creator><creator>Rangarajan, Venkatesh</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2581-3086</orcidid><orcidid>https://orcid.org/0000-0002-5133-7442</orcidid><orcidid>https://orcid.org/0000-0002-3509-4794</orcidid><orcidid>https://orcid.org/0000-0002-3560-9655</orcidid><orcidid>https://orcid.org/0000-0002-8385-2836</orcidid><orcidid>https://orcid.org/0000-0001-9989-5534</orcidid><orcidid>https://orcid.org/0000-0002-4323-753X</orcidid><orcidid>https://orcid.org/0000-0001-7657-3460</orcidid></search><sort><creationdate>202111</creationdate><title>Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy</title><author>Laskar, Siddhartha ; Kakoti, Sangeeta ; Khanna, Nehal ; Manjali, Jifmi Jose ; Mangaj, Akshay ; Puri, Ajay ; Gulia, Ashish ; Nayak, Prakash ; Pai, Prathamesh ; Nair, Deepa ; Qureshi, Sajid ; Chinnaswamy, Girish ; Bajpai, Jyoti ; Prabhash, Kumar ; Rekhi, Bharat ; Ramadwar, Mukta ; Jambhekar, Nirmala ; Janu, Amit ; Juvekar, Sashikant ; Purandare, Nilendu ; Rangarajan, Venkatesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-a49a0b766cd6dc32536ef3d7e85524e9400f283f128cd5fcdf795d8a36d0fc3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bone Neoplasms</topic><topic>Chondrosarcoma - radiotherapy</topic><topic>Chordoma - radiotherapy</topic><topic>Dose escalation</topic><topic>Humans</topic><topic>Intensity modulated radiotherapy</topic><topic>Life Sciences & Biomedicine</topic><topic>Oncology</topic><topic>Osteosarcoma - radiotherapy</topic><topic>Prospective Studies</topic><topic>Radiology, Nuclear Medicine & Medical Imaging</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, Intensity-Modulated - adverse effects</topic><topic>Sarcoma</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laskar, Siddhartha</creatorcontrib><creatorcontrib>Kakoti, Sangeeta</creatorcontrib><creatorcontrib>Khanna, Nehal</creatorcontrib><creatorcontrib>Manjali, Jifmi Jose</creatorcontrib><creatorcontrib>Mangaj, Akshay</creatorcontrib><creatorcontrib>Puri, Ajay</creatorcontrib><creatorcontrib>Gulia, Ashish</creatorcontrib><creatorcontrib>Nayak, Prakash</creatorcontrib><creatorcontrib>Pai, Prathamesh</creatorcontrib><creatorcontrib>Nair, Deepa</creatorcontrib><creatorcontrib>Qureshi, Sajid</creatorcontrib><creatorcontrib>Chinnaswamy, Girish</creatorcontrib><creatorcontrib>Bajpai, Jyoti</creatorcontrib><creatorcontrib>Prabhash, Kumar</creatorcontrib><creatorcontrib>Rekhi, Bharat</creatorcontrib><creatorcontrib>Ramadwar, Mukta</creatorcontrib><creatorcontrib>Jambhekar, Nirmala</creatorcontrib><creatorcontrib>Janu, Amit</creatorcontrib><creatorcontrib>Juvekar, Sashikant</creatorcontrib><creatorcontrib>Purandare, Nilendu</creatorcontrib><creatorcontrib>Rangarajan, Venkatesh</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laskar, Siddhartha</au><au>Kakoti, Sangeeta</au><au>Khanna, Nehal</au><au>Manjali, Jifmi Jose</au><au>Mangaj, Akshay</au><au>Puri, Ajay</au><au>Gulia, Ashish</au><au>Nayak, Prakash</au><au>Pai, Prathamesh</au><au>Nair, Deepa</au><au>Qureshi, Sajid</au><au>Chinnaswamy, Girish</au><au>Bajpai, Jyoti</au><au>Prabhash, Kumar</au><au>Rekhi, Bharat</au><au>Ramadwar, Mukta</au><au>Jambhekar, Nirmala</au><au>Janu, Amit</au><au>Juvekar, Sashikant</au><au>Purandare, Nilendu</au><au>Rangarajan, Venkatesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy</atitle><jtitle>Radiotherapy and oncology</jtitle><stitle>RADIOTHER ONCOL</stitle><addtitle>Radiother Oncol</addtitle><date>2021-11</date><risdate>2021</risdate><volume>164</volume><spage>216</spage><epage>222</epage><pages>216-222</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract><![CDATA[•Dose-escalated IG-IMRT results in good LC & CSS in OGS, CS and CH of H&N and pelvis.•No significant difference in outcomes for definitive versus post-operative RT.•Significant and sustained benefit in functional outcomes after RT.•Acute & late toxicities were minimal despite escalated doses.•Salvage re-RT is feasible and efficacious in recurrence after dose-escalated IG-IMRT.
To evaluate the efficacy and toxicity of dose-escalated image guided-intensity modulated radiation therapy (IG-IMRT) in osteosarcoma (OGS), chondrosarcoma (CS) and chordoma (CH) of head and neck (H&N) and pelvis.
In this prospective non-randomized study, 65 patients of H&N or pelvic OGS (24), CS (7) and CH (34) mandating definitive or post-operative radiotherapy from May 2013 to December 2018 were included. Radiotherapy doses in definitive setting were 72.0 Gy for CH and 70.2 Gy for OGS and CS; while in post-operative setting it was 66.6 Gy and 64.8 Gy respectively (at 1.8 Gy per fraction).
Planned doses of radiotherapy could be completed in 61 (93.8%) patients; with grade III or higher acute and late toxicities of 3% and 0% respectively. With a median follow-up of 52 (range 6–92) months, the five-year actuarial local control (LC) rates were 66% in OGS, 38.1% in CS and 75.9% in CH; while cause-specific survival (CSS) rates were 54.7%, 64.3% and 92.2% respectively. There was no statistically significant difference in outcomes for patients receiving definitive and post-operative radiotherapy. Locally controlled disease at first follow-up after radiotherapy was associated with improved CSS and OS in CS (p = 0.014) and CH (p < 0.001). Radiotherapy resulted in significant and sustained improvement in Musculoskeletal tumour society (MSTS) score and reduction in pain score. Salvage re-irradiation was feasible in local progression after radiotherapy, with good outcomes and tolerability.
Dose-escalated IG-IMRT results in good LC & functional improvement with minimal toxicity in OGS, CS and CH.]]></abstract><cop>CLARE</cop><pub>Elsevier B.V</pub><pmid>34597737</pmid><doi>10.1016/j.radonc.2021.09.018</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2581-3086</orcidid><orcidid>https://orcid.org/0000-0002-5133-7442</orcidid><orcidid>https://orcid.org/0000-0002-3509-4794</orcidid><orcidid>https://orcid.org/0000-0002-3560-9655</orcidid><orcidid>https://orcid.org/0000-0002-8385-2836</orcidid><orcidid>https://orcid.org/0000-0001-9989-5534</orcidid><orcidid>https://orcid.org/0000-0002-4323-753X</orcidid><orcidid>https://orcid.org/0000-0001-7657-3460</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-8140 |
| ispartof | Radiotherapy and oncology, 2021-11, Vol.164, p.216-222 |
| issn | 0167-8140 1879-0887 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2578772534 |
| source | MEDLINE; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Access via ScienceDirect (Elsevier) |
| subjects | Bone Neoplasms Chondrosarcoma - radiotherapy Chordoma - radiotherapy Dose escalation Humans Intensity modulated radiotherapy Life Sciences & Biomedicine Oncology Osteosarcoma - radiotherapy Prospective Studies Radiology, Nuclear Medicine & Medical Imaging Radiotherapy Dosage Radiotherapy, Intensity-Modulated - adverse effects Sarcoma Science & Technology |
| title | Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T23%3A08%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20osteosarcoma,%20chondrosarcoma%20and%20chordoma%20treated%20with%20image%20guided-intensity%20modulated%20radiation%20therapy&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Laskar,%20Siddhartha&rft.date=2021-11&rft.volume=164&rft.spage=216&rft.epage=222&rft.pages=216-222&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/j.radonc.2021.09.018&rft_dat=%3Cproquest_webof%3E2578772534%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2578772534&rft_id=info:pmid/34597737&rft_els_id=S0167814021067414&rfr_iscdi=true |